Skip to content

Public FDA record

Z-0749-2022: Alinity s System software version2.8.0, REF LN 06P16-01, IVD, OEI: (01)00380740138479 The Alinity s Syst

Recall record Z-0749-2022 for Abbott Laboratories, Inc. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-0749-2022
Company in FDA record
Abbott Laboratories, Inc
FDA record creation date
Mar 11, 2022
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

Software error associated with the immunoassay analyzer wash cycle which is using 1 mL of wash buffer instead of the intended 3 mL of wash buffer to wash the exterior of the probe.

Source facts

Action
On February 3, 2022, Abbott issued two "Urgent Product Correction" notifications. For US customers these notification where delivered by Abbott personnel. For OUS consignees letters were provided by Abbott personnel or by email. During the week of February 25, 2022, an updated letter was provided to US customers containing additional information. In addition to informing consignees about the recall the firm provided the following instructions Please perform the necessary immediate actions, if utilizing the Alinity s HIV Ag/Ab Combo and Alinity s Anti-HCV II assays while operating on Alinity s System SW version 2.8.0, to continue to use the Alinity s System. These actions mitigate potential impact for false reactive results when using the Alinity s HIV Ag/Ab Combo Reagent kit. The Alinity s HIV Ag/Ab Combo and Alinity s Anti-HCV II assays are not installed or do not run on the same Alinity s System. - No action is required. The Alinity s Anti-HCV II assay is not calibrated and run on the same processing lane as the Alinity s HIV Ag/Ab Combo assay. - Maintain the current assay configuration and ensure the Alinity s HIV Ag/Ab Combo assay is not run on the same processing lane as the Alinity s Anti-HCV II assay. The Alinity s Anti-HCV II assay and the Alinity s HIV Ag/Ab Combo assay are calibrated and run on the same processing lane. - Contact your local area customer service representative to assess the configuration and uninstall/reinstall the assays to run on separate processing lanes or instruments. Please review this letter with your Medical Director or Laboratory Management and follow your laboratory protocol regarding the need for reviewing previously reported Alinity s HIV Ag/Ab Combo assay test results while operating on Alinity s System SW version 2.8.0. If you have forwarded the product listed above to other laboratories, please inform them of this Product Correction and provide to them a copy of this letter. Please complete and return the Customer Re
Initiated
2022-02-03
Root cause
Under Investigation by firm
Distribution
Worldwide distribution: US (nationwide) including states of: AL, CA, GA, IL, IN, MN, MO, NC, OK, PA, RI, SC, TN, TX, WA, WI, MD and countries (OUS) including of: Australia, Austria, Bahrain, Belgium, Brazil, china, Colombia, Croatia, Cyprus, Czech Republic, Egypt, Germany, Greece, Hong Kong, Hungary, Iran, Ireland, Israel, Italy, Jordan Kuwait and Mexico.
Recall number
Z-0749-2022
Recall status
Open, Classified
CDRH record ID
192038
FDA record created
2022-03-11
Recall event number
89604

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗